Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5804-5812

  Yamamoto, Takehito ^a,b   Yasuno, Nobuhiro ^a,b,c   Katada, Shoichi ^a,b,d   Hisaka, Akihiro ^a,b   Hanafusa, Norio ^a,b   Noiri, Eisei ^a,b   Yahagi, Naoki ^a,b   Fujita, Toshiro ^a,b   Suzuki, Hiroshi ^a,b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kan etsu Hospital   (Japan)

^d SENDAI CITY MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; POLYACRYLONITRILE; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG ADSORPTION; DRUG CLEARANCE; FEMALE; HEMODIAFILTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MALE; PLASMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMODIAFILTRATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NOMOGRAMS; TEICOPLANIN; VANCOMYCIN; YOUNG ADULT;

EID: 81555206668     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01758-10     Document Type: Article

References (49)

1. Albrecht, L. M., M. J. Rybak, L. H. Warbasse, and D. J. Edwards. 1991. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25:713-715.
2. Arzuaga, A., et al. 2006. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif. 24:347-354. (Pubitemid 44215178)
3. Barbot, A., et al. 2003. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 29:1528-1534. (Pubitemid 37153597)
4. Beaucaire, G., et al. 1991. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J. Antimicrob. Chemother. 27(Suppl. C):91-103.
5. Bellomo, R., et al. 2009. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med. 361:1627-1638.
6. Berezhkovskiy, L. M. 2006. Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal. J. Pharmacokinet. Pharmacodyn. 33:595-608. (Pubitemid 44386859)
7. Bonati, M., et al. 1987. Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin. Pharmacokinet. 12:292-301. (Pubitemid 17072060)
8. Bouman, C. S., et al. 2006. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med. 32:2013-2019. (Pubitemid 44833115)
9. Cerda, J., and C. Ronco. 2009. Modalities of continuous renal replacement therapy: technical and clinical considerations. Semin. Dial. 22:114-122.
10. Choi, G., et al. 2009. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med. 37:2268-2282.
11. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
12. Dalhoff, A., P. G. Ambrose, and J. W. Mouton. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305.
13. Davis, R. L., D. Lehmann, C. A. Stidley, and J. Neidhart. 1991. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob. Agents Chemother. 35:944-947.
14. EUCAST (European Committee on Antimicrobial Susceptibility Testing). 2011. Breakpoint tables for interpretation of MICs and zone diameters (version 1.3, January 5, 2011). http://www.eucast.org/fileadmin/src/media/PDFs /EUCAST-files/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf.pdf.
15. Eyler, R. F., and B. A. Mueller. 2011. Antibiotic dosing in critically ill patients with acute kidney injury. Nat. Rev. Nephrol. 7:226-235.
16. Geraci, J. E., F. R. Heilman, D. R. Nichols, and W. E. Wellman. 1958. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc. Staff Meet. Mayo Clin. 33:172-181.
17. Gilbert, D. N., R. C. Moellering, Jr., G. M. Eliopoulos, and M. A. Sande (ed.). 2011. The Sanford Guide to antimicrobial therapy 2011. Antimicrobial Therapy Inc., Sperryville, VA.
18. Golper, T. A. 2001. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib. Nephrol. 132:349-353.
19. Gould, I. M. 2010. Is vancomycin redundant for serious staphylococcal infection? Int. J. Antimicrob. Agents 36(Suppl. 2):S55-S57.
20. Hayakawa, M., I. Fujita, K. Iseki, and S. Gando. 2009. The administration of ciprofloxacin during continuous renal replacement therapy: pilot study. ASAIO J. 55:243-245.
21. Isla, A., et al. 2007. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy 53:194-201. (Pubitemid 46581993)
22. Joy, M. S., G. R. Matzke, R. F. Frye, and P. M. Palevsky. 1998. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am. J. Kidney Dis. 31:1019-1027. (Pubitemid 28265200)
23. Kuti, J. L., C. R. Kiffer, C. M. Mendes, and D. P. Nicolau. 2008. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin. Microbiol. Infect. 14:116-123.
24. Layeux, B., F. S. Taccone, D. Fagnoul, J. L. Vincent, and F. Jacobs. 2010. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:4939-4941.
25. Lodise, T. P., et al. 2007. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J. Antimicrob. Chemother. 60:1038-1044. (Pubitemid 47617751)
26. MacGowan, A. P., and R. Wise. 2001. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J. Antimicrob. Chemother. 48(Suppl. 1):17-28.
27. Mimoz, O., et al. 2006. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 32:775-779.
28. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99. (Pubitemid 17225088)
29. Niwa, T., et al. 2004. Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic. Jpn. J. Antibiot. 57:413-419. (In Japanese.) (Pubitemid 39243656)
30. Pea, F., et al. 2004. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin. Pharmacokinet. 43:405-415. (Pubitemid 38594713)
31. Pea, F., P. Viale, F. Pavan, and M. Furlanut. 2007. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin. Pharmacokinet. 46:997-1038. (Pubitemid 350136909)
32. Roberts, J. A., and J. Lipman. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37:840-851.
33. Rodvold, K. A., R. D. Pryka, M. Garrison, and J. C. Rotschafer. 1989. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther. Drug Monit. 11:269-275. (Pubitemid 19115158)
34. Ronco, C., et al. 2000. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26-30. (Pubitemid 30416991)
35. Rowland, M. 1990. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 18:184-209. (Pubitemid 20109453)
36. Rybak, M. J., et al. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327.
37. Scaglione, F., and L. Paraboni. 2008. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int. J. Antimicrob. Agents 32:294-301.
38. Susla, G. M. 2009. The impact of continuous renal replacement therapy on drug therapy. Clin. Pharmacol. Ther. 86:562-565.
39. Svetitsky, S., L. Leibovici, and M. Paul. 2009. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob. Agents Chemother. 53:4069-4079.
40. Taccone, F. S., et al. 2010. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit. Care 14:R53.
41. Thummel, K. E., D. D. Shen, N. Isoherranen, and H. E. Smith. 2006. Design and optimization of dosage regimens, pharmacokinetic data, p. 1787-1888. In L. L. Brunton (ed.), Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. McGraw Hill Companies, Chicago, IL.
42. Tian, Q., et al. 2008. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob. Agents Chemother. 52:1009-1013. (Pubitemid 351358381)
43. Tobin, C. M., A. M. Lovering, E. Sweeney, and A. P. MacGowan. 2010. Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. J. Antimicrob. Chemother. 65:2155-2157.
44. Tolwani, A. J., et al. 2008. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J. Am. Soc. Nephrol. 19:1233-1238.
45. Traber, P. G., and D. P. Levine. 1981. Vancomycin ototoxicity in patient with normal renal function. Ann. Intern. Med. 95:458-460. (Pubitemid 11007379)
46. Trotman, R. L., J. C. Williamson, D. M. Shoemaker, and W. L. Salzer. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41:1159-1166. (Pubitemid 41429480)
47. Wagner, J. G. 1975. Fundamentals of clinical pharmacokinetics, 1st ed. Drug Intelligence Publications, Inc., Hamilton, IL.
48. Wolter, K., M. Claus, and E. Fritschka. 1994. Pharmacokinetics and dosage recommendations of teicoplanin in patients treated by continuous venovenous haemodialysis (CVVHD). Eur. J. Clin. Pharmacol. 46:179-180. (Pubitemid 24101340)
49. Wolter, K., M. Claus, K. Wagner, and E. Fritschka. 1994. Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis. Clin. Nephrol. 42:389-397.